DOV
64
-5
T
56
2
FTI
82
4
EL
30
-3
MOS
19
-4
LEN
55
-9
NKE
46
12
DOW
58
-5
KSS
39
6
TROW
34
-5
TGT
50
-2
MPC
52
8
FLS
56
-3
FIS
46
-4
ALLE
57
-7
CMG
51
-3
MUR
50
-2
UAL
56
2
RF
51
-2
LEG
27
-2
DOV
64
-5
T
56
2
FTI
82
4
EL
30
-3
MOS
19
-4
LEN
55
-9
NKE
46
12
DOW
58
-5
KSS
39
6
TROW
34
-5
TGT
50
-2
MPC
52
8
FLS
56
-3
FIS
46
-4
ALLE
57
-7
CMG
51
-3
MUR
50
-2
UAL
56
2
RF
51
-2
LEG
27
-2
Financhill
Back

NewAmsterdam Pharma Co NV 10K Form

Sell
23

NAMS
NewAmsterdam Pharma Co NV

Last Price:
15.90
Seasonality Move:
4.65%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive NAMS News And Ratings

See the #1 stock for the next 7 days that we like better than NAMS

NAMS Financial Statistics

Sales & Book Value

Annual Sales: $14.09M
Cash Flow: $-54.19M
Price / Cash Flow: 0
Annual Sales: $4.30
Price / Book: 3.69

Profitability

EPS (TTM): -2.45000
Net Income (TTM): $-213.08M
Gross Margin: --
Return on Equity: -56.65%
Return on Assets: -44.17%

NewAmsterdam Pharma Co NV Earnings Forecast

Key NewAmsterdam Pharma Co NV Financial Ratios

  • The Research & Development expenses have been 1,131.47% of Revenue.
  • The Interest Expense is 0.00% of Operating Income.
  • The Net Earning history of NAMS is -1,255.76% of Total Revenues.
  • Per Share Earnings over the last 4 years have been positive in 0 years.

NewAmsterdam Pharma Co NV Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: NAMS
Website: newamsterdampharma.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 9.83
Quick Ratio: 9.63

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

NAMS Technical Analysis vs Fundamental Analysis

Sell
23
NewAmsterdam Pharma Co NV (NAMS) is a Sell

Is NewAmsterdam Pharma Co NV a Buy or a Sell?